Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference

Genocea Biosciences, Inc. (NASDAQ: GNCA) will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 8:40 A.M.

Rhea-AI Summary

Genocea Biosciences, Inc. (NASDAQ: GNCA) will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on March 17, 2022, at 8:40 A.M. ET. Chip Clark, President and CEO, will lead the discussion. A live webcast will be accessible on the investor relations section of Genocea's website, with a replay available for 90 days. Genocea focuses on neoantigen immunotherapies to treat cancer, utilizing its ATLAS™ platform for personalized T cell responses. The company is currently conducting clinical trials for GEN-011 and GEN-009 therapies.

Argus Session date unavailable

-1.77% session move Open Argus

Details

News Market Reaction – GNCA

The recorded move for GNCA in the trading session of this news was -1.77%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17^th at 8:40 A.M. ET.

A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at https://ir.genocea.com/events-presentations. A replay of the webcast will be archived for 90 days following the presentation.

About Genocea Biosciences, Inc.
Genocea’s mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS™ platform can comprehensively profile each patient’s T cell responses to potential targets, or antigens, on that patient’s tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, Inhibigens™, that drive pro-tumor immune responses. We are conducting a Phase 1/2a clinical trial for GEN-011, our investigational adoptive T cell therapy comprising neoantigen-targeted peripheral cells. We continue to monitor patients in our phase 1/2a clinical trial for GEN-009, our investigational neoantigen vaccine. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.

Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Genocea's presentation at the Oppenheimer Healthcare Conference?

Genocea's presentation is scheduled for March 17, 2022, at 8:40 A.M. ET.

Who is presenting for Genocea at the Oppenheimer Healthcare Conference?

Chip Clark, the President and CEO of Genocea, will present.

Where can I watch the live webcast of Genocea's conference presentation?

The live webcast will be available in the 'Events and Presentations' section of Genocea's investor relations website.

What is the focus of Genocea's clinical trials?

Genocea is conducting clinical trials for GEN-011, an adoptive T cell therapy, and GEN-009, a neoantigen vaccine.

What technology does Genocea use for its cancer treatments?

Genocea utilizes its proprietary ATLAS™ platform to profile T cell responses for personalized immunotherapy.